Veröffentlichungsdatum: 28 April 2020
Projektträger – zwischengeschaltetes Finanzinstitut
GALENICUM HEALTH SL
The project will finance the promoter's pharmaceutical RDI and expansion investments in Spain.
The EIB loan will be used to support the implementation of the company's strategy. The investments are expected to support the promoter's competitiveness and growth.
- Industrie - Verarbeitendes Gewerbe/Herstellung von Waren
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 20 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 50 million
All aspects related to the environmental impact and permits will be verified during the project's appraisal.
The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rule on public procurement.
Unterzeichnet - 14/01/2021
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).